The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion.

IF 1.8 4区医学 Q3 ONCOLOGY

Oncology-New York Pub Date : 2024-11-05 DOI:10.46883/2024.25921028

Fnu Fatima, Faryal Arif, Muhammad Hamza Gul, Neha Siddiqui, Muhammad Zulqarnain, Abdul Baseer Wardak

引用次数: 0

Abstract

We present a 65-year-old man with multiple myeloma who developed a rare complication of pleural effusion. Initial laboratory results showed elevated creatinine, calcium, and protein electrophoresis with an M spike. A bone marrow biopsy confirmed 80% plasma cells. Despite the rarity of pleural effusion in patients with multiple myeloma, our patient demonstrated significant improvement with targeted therapy and palliative care. This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.

查看原文本刊更多论文

隐藏的危险揭开多发性骨髓瘤与胸腔积液之间的联系

我们为大家介绍一位 65 岁的多发性骨髓瘤患者，他出现了罕见的胸腔积液并发症。初步化验结果显示血肌酐、血钙升高，蛋白质电泳出现 M 峰。骨髓活检证实 80% 为浆细胞。尽管胸腔积液在多发性骨髓瘤患者中十分罕见，但我们的患者在接受靶向治疗和姑息治疗后病情明显好转。本病例强调了早期识别和处理多发性骨髓瘤患者胸腔积液的重要性，并强调了进一步研究最佳治疗策略和潜在机制的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology-New York 肿瘤学-肿瘤学

CiteScore

1.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.